Form 4 for MNPR Monopar Therapeutics
Accepted 2023-01-03 00:00:00 ET · period of report 2022-12-31 · accession 0001437749-23-000166 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Tsuchimoto Kim R | CFO | F - Tax | $2.37 | -2,569 | 17.8K | -13% | -$6,089 |
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Tsuchimoto Kim R | CFO | M - OptEx | — | +6,297 | 19.8K | +46% | — |
| DM | 2023-01-03 | 2022-12-31+ | MNPR | Tsuchimoto Kim R | CFO | M - OptEx | $0.00 | -6,297 | 55.9K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-01 | F | D | 502 | $2.37 | 18,507 | D | — | — | |
| 2 | Common | Common Stock | 2023-01-01 | M | A | 1,230 | — | 19,009 | D | — | — | (F1) Represents shares acquired on vesting and settlement of restricted stock units. |
| 3 | Common | Common Stock | 2022-12-31 | M | A | 5,067 | — | 19,846 | D | — | — | (F1) Represents shares acquired on vesting and settlement of restricted stock units. |
| 4 | Common | Common Stock | 2022-12-31 | F | D | 2,067 | $2.37 | 17,779 | D | — | — | |
| 5 | Derivative | Restricted Stock Units | 2023-01-01 | M | D | 1,230 | $0.00 | 1,231 | D | — · — to — | 1,230 Common Stock | (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F4) On January 31, 2020, the reporting person was granted 4,923 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |
| 6 | Derivative | Restricted Stock Units | 2022-12-31 | M | D | 5,067 | $0.00 | 55,917 | D | — · — to — | 5,067 Common Stock | (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F3) On February 2, 2022, the reporting person was granted 61,532 restricted stock units, vesting 6/48ths (7,692 shares) on June 30, 2022, and 3/48ths (3,846 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. (F2) On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |